Beta-Lactam Antibiotics: Clinical Overview

Infectious Disease / Antimicrobials

🦠 Beta-Lactam Antibiotics: Clinical Overview

A PharmD reference covering the major beta-lactam classes: penicillins, cephalosporins, carbapenems, and monobactams. Includes spectrum of activity, key clinical uses, cross-reactivity considerations, and PK/PD optimization principles.

Classes and Spectrum Overview

Class	Examples	Key Gram+	Key Gram−	Anaerobes
Aminopenicillins	Ampicillin, Amoxicillin	Streptococci, Enterococcus faecalis	Some E. coli, H. influenzae (susceptibility varies)	Limited
Beta-lactam/BLI combos	Pip-tazo, Amox-clav, Amp-sulbactam	Streptococci, MSSA, some Enterococcus	Extended GNR coverage including many ESBL (pip-tazo variable)	Good (pip-tazo, amp-sulbactam)
1st gen cephalosporins	Cefazolin, Cephalexin	MSSA, Streptococci	Modest (E. coli, Klebsiella, Proteus mirabilis)	None
3rd gen cephalosporins	Ceftriaxone, Cefdinir, Ceftazidime	Streptococci (weak MSSA)	Broad GNR; ceftazidime covers Pseudomonas	None
4th gen cephalosporins	Cefepime	MSSA, Streptococci	Broad including Pseudomonas	None
5th gen cephalosporins	Ceftaroline	MRSA, Streptococci	Broad GNR (not Pseudomonas)	None
Carbapenems	Meropenem, Imipenem, Ertapenem	MSSA, Streptococci (not MRSA)	Very broad; meropenem/imipenem cover Pseudomonas (ertapenem does not)	Excellent
Monobactams	Aztreonam	None	Gram-negative only (including Pseudomonas); no activity vs. gram+	None

PK/PD Optimization

Beta-lactams exhibit time-dependent killing: efficacy correlates with the percentage of the dosing interval that free drug concentrations exceed the MIC (%fT>MIC), not with peak concentration.

Strategy	Application	Evidence
Extended infusion	Infuse beta-lactam over 3–4h instead of 30 min. Maximizes %fT>MIC at steady state. Most applicable to piperacillin-tazobactam, meropenem, cefepime.	Multiple PK/PD studies; preferred in critically ill patients and/or resistant organisms. Some RCT data for mortality benefit in severe infections.
Continuous infusion	24h continuous IV infusion to maintain constant drug exposure. Requires stability data.	Stability limits: pip-tazo stable ~12h at room temp; meropenem stable ~8h. Requires dedicated IV access.
Higher doses	For organisms with intermediate susceptibility or in CNS infections where drug penetration is lower.	Meropenem 2 g q8h for CNS infections; cefepime 2 g q8h for Pseudomonas.

Cross-Reactivity & Penicillin Allergy

The historically cited 10% cross-reactivity rate between penicillins and cephalosporins is a myth based on outdated data contaminated by penicillin impurities. Current evidence:

True cross-reactivity rate is <1–2% for structurally dissimilar cephalosporins
Cross-reactivity is driven by the R1 side chain similarity, not the beta-lactam ring itself
Cefazolin shares no R1 side chain similarity with ampicillin/amoxicillin, so it is extremely safe in penicillin-allergic patients
Patients with penicillin allergy labels should undergo allergy risk stratification: the vast majority can safely receive cephalosporins and carbapenems
Aztreonam shares an R1 side chain with ceftazidime. Avoid aztreonam in patients with proven ceftazidime allergy

💡 Penicillin allergy delabeling is one of the highest-impact interventions a clinical pharmacist can lead. Documented penicillin allergy is associated with worse outcomes, longer LOS, and increased C. difficile rates. Consider allergy stewardship as a core pharmacist function.

PharmD Clinical Pearls

💡 The vancomycin + pip-tazo nephrotoxicity signal from observational studies was not confirmed by the 2023 ACORN randomized trial (no AKI difference vs. cefepime), and may partly reflect pseudotoxicity from creatinine-secretion interference. Consider cefepime or meropenem in patients at high AKI risk, but the association is no longer considered settled.

💡 Cefepime can cause neurotoxicity (encephalopathy, myoclonus, seizures), particularly in patients with renal impairment who are not dose-adjusted. Brain MRI may be normal; EEG shows triphasic waves. Stop cefepime and toxicity resolves.

💡 Ertapenem does NOT cover Pseudomonas or Acinetobacter. Do not use for hospital-acquired or ventilator-associated pneumonia empirically.

💡 Beta-lactam stability matters for extended infusion. Piperacillin-tazobactam is unstable at room temperature beyond ~12h; must be refrigerated or reconstituted fresh. Plan infusion bags accordingly.

🎓

Reviewed by a licensed pharmacist

Reference content reviewed for clinical accuracy. This is not a substitute for institutional protocols or professional judgment.

← Back to Clinical Reference · Literature Archive →